Dépistage et prise en charge du trouble bipolaire : Résultats

Llorca, Pierre‐Michel; Courtet, Philippe; Martín, P.J. Rodríguez; Abbar, Mocrane; Gay, Christian; Meynard, Jean-Albert; Baylé, Franck; Hamon, Michel; Lançon, Christophe; Thibaut, Florence; Thomas, Pierre; Lancrenon, S.; Guillaume, Sébastien; Samalin, Ludovic

doi:10.1016/s0013-7006(10)70037-3

Cited by 31 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On peut simplement citer en première intention la mise en place de mesures hygiéno-diététiques (rythme régulier, sommeil, alimentation équilibrée, activité physique…) et l'utilisation de thérapies cognitives comportementale. (11,35).…”

Section: Le Traitementunclassified

Formation continue des préparateurs en pharmacie hospitalière : développement d’une formation ludique dans la prise en charge médicamenteuse en psychiatrie

Giannoni¹,

Chanoine²,

Minischetti³

et al. 2022

Le Pharmacien Clinicien

View full text Add to dashboard Cite

Section: Le Traitementunclassified

Formation continue des préparateurs en pharmacie hospitalière : développement d’une formation ludique dans la prise en charge médicamenteuse en psychiatrie

Giannoni¹,

Chanoine²,

Minischetti³

et al. 2022

Le Pharmacien Clinicien

View full text Add to dashboard Cite

“…Despite these and other challenges, high-quality practice guidelines for managing bipolar disorders in pregnant and postpartum women have been developed, 22 , 230 , 233 , 234 and treatment considerations for this population are covered in general bipolar disorder-treatment guidelines. 77 , 90 , 235 , 236 A detailed review of recommended approaches for treating acute mood episodes or preventing their recurrence during pregnancy is beyond the scope of this review. However, some of these guidelines provide consistent recommendations in several key areas, 237 including the importance of discussing reproductive and obstetric risks associated with pharmacotherapies in all women with bipolar disorder who are of reproductive age, even prior to formal preconception planning.…”

Section: Summary and Clinical Implicationsmentioning

confidence: 99%

Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges

Epstein¹,

Moore

Bobo

2014

DHPS

View full text Add to dashboard Cite

Treating pregnant women with bipolar disorder is among the most challenging clinical endeavors. Patients and clinicians are faced with difficult choices at every turn, and no approach is without risk. Stopping effective pharmacotherapy during pregnancy exposes the patient and her baby to potential harms related to bipolar relapses and residual mood symptom-related dysfunction. Continuing effective pharmacotherapy during pregnancy may prevent these occurrences for many; however, some of the most effective pharmacotherapies (such as valproate) have been associated with the occurrence of congenital malformations or other adverse neonatal effects in offspring. Very little is known about the reproductive safety profile and clinical effectiveness of atypical antipsychotic drugs when used to treat bipolar disorder during pregnancy. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated or undertreated maternal bipolar disorder during pregnancy, the effectiveness of interventions for bipolar disorder management during pregnancy, and potential obstetric, fetal, and neonatal risks associated with core foundational pharmacotherapies for bipolar disorder.

show abstract

“…It was of interest to determine the rank of use of asenapine with respect to the other SGAs in clinical practice. Overall guidelines for the management of bipolar disorder recommend lithium, valproate or a SGA as first-line treatment in acute manic episodes [Goodwin, 2009;Grunze et al 2009;Llorca et al 2010;Malhi et al 2009;Yatham et al 2009]. A meta-analysis assessed the efficacy of 17 available antimanic drugs from 38 randomized, placebo-controlled studies for acute mania or mixed episodes involving 10,800 patients [Yildiz et al 2011].…”

Section: Place Of Asenapine In Clinical Practice In the Management Ofmentioning

confidence: 99%

“…More recently, second-generation antipsychotics (SGAs) have emerged in bipolar disorder as an option for the treatment of depressive or manic episodes and for maintenance treatment. In guidelines, these medications are recommended as first-line treatment for mania, and quetiapine or olanzapine as first-line treatment for bipolar depression [Goodwin, 2009;Grunze et al 2009;Llorca et al 2010;Malhi et al 2009;Yatham et al 2009]. Some SGAs may be somewhat more efficacious or more tolerated than others.…”

Section: Introductionmentioning

confidence: 99%

Asenapine in bipolar I disorder: evidence and place in patient management

Samalin

Charpeaud

Llorca

2012

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Asenapine is a new second-generation antipsychotic approved in September 2010 by the European Medicines Agency for the treatment of bipolar disorder. It demonstrated significant efficacy compared with placebo in acute mania or mixed episodes as monotherapy or adjunctive therapy to mood stabilizers (lithium or valproate). Early improvement was noted at day 2 and was strongly associated with response and remission at week 3. Asenapine also appeared effective in treating acute mania in older patients with bipolar disorder. Post hoc analyses of asenapine showed efficacy in treating depressive symptoms during manic or mixed episodes compared with placebo. The efficacy of asenapine in patients with acute mania appeared to remain constant during maintenance treatment. Asenapine was reasonably well tolerated, especially with regard to metabolic effects. There were minimal signs of glucose elevation or lipid changes and the risk of weight gain appeared limited. The prolactin elevation was smaller than other antipsychotic comparators. Only oral hypoesthesia occurred as a new adverse event compared with other second-generation antipsychotics. Asenapine presents several advantages over other second-generation antipsychotics, such as sublingual formulation, early efficacy and good metabolic tolerability. This tolerability profile confirms the heterogeneity of the second-generation antipsychotic class and supports the view of some authors for the need to re-evaluate the boundaries of this group.

show abstract

Dépistage et prise en charge du trouble bipolaire : Résultats

Cited by 31 publications

References 6 publications

Formation continue des préparateurs en pharmacie hospitalière : développement d’une formation ludique dans la prise en charge médicamenteuse en psychiatrie

Formation continue des préparateurs en pharmacie hospitalière : développement d’une formation ludique dans la prise en charge médicamenteuse en psychiatrie

Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges

Asenapine in bipolar I disorder: evidence and place in patient management

Contact Info

Product

Resources

About